PAREXEL International Corporation (PRXL) Releases Earnings Results, Beats Expectations By $0.01 EPS

PAREXEL International Corporation (PRXL) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $0.94 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $0.93. The company posted revenue of $538.60 million in the period, compared to analysts expectations of $532.59 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.

Many Wall Street Analysts have commented on PAREXEL International Corporation. Credit Suisse Initiated PAREXEL International Corporation on Jun 21, 2016 to “Outperform”, Price Target of the shares are set at $75.

PAREXEL International Corporation closed down -0.94 points or -1.39% at $66.47 with 3,68,222 shares getting traded on Tusday. Post opening the session at $67.46, the shares hit an intraday low of $65.88 and an intraday high of $67.46 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jun 14, 2016, A Dana Jr Callow (director) sold 3,000 shares at $60.04 per share price. According to the SEC, on Jun 3, 2016, Eduard E. Holdener (director) sold 700 shares at $62.98 per share price. On May 26, 2016, Ulf I Schneider (SVP & Chief Admin. Officer) sold 7,500 shares at $62.00 per share price, according to the Form-4 filing with the securities and exchange commission.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

PAREXEL International Corporation

Leave a Reply

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.